MCG Post Myocardial Infarction Study

Creavo Medical Technologies Ltd50 enrolled

Overview

The study is being performed to evaluate a new portable medical device, the Creavo Vitalscan Magnetocardiograph (Vitalscan) on patients who have had a confirmed myocardial infarction (heart attack) within the previous 12 weeks.

Magnetocardiography (MCG) is a non-contact, passive, imaging technique that detects the magnetic fields generated by the electrical activity of the heart. The MCG technology has been evaluated in several clinical studies, demonstrating its potential usefulness in the detection of patients with stable angina and acute coronary syndrome (ACS), including non-ST segment elevation myocardial infarction (NSTEMI). Previous studies have been completed using earlier versions of the Vitalscan device. Results showed that the device could differentiate between patients with confirmed ischaemic heart disease (IHD) and NSTEMI, those with non-IHD experiencing chest pain and healthy (non-ischaemic) control subjects. The aim of this pilot study is to assess the difference between abnormal MCG images from patients with a confirmed and recent myocardial infarction (MI)and normal images from previously obtained healthy volunteer controls scanned with the current device, so that comparisons can be made to the data acquired from the previous studies.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Myocardial Infarction

Interventions

VitalscanDEVICE

Vitalscan is a magnetocardiograph device

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with confirmed myocardial infarction within 12 weeks of the initial event * Patients admitted to the Coronary Care Unit (CCU) at Warwick Hospital on the point of discharge or patients already discharged from the CCU attending the cardiac rehabilitation classes * 18+ year old male or female * Patient is willing and able to give written informed consent Exclusion Criteria: * Atrial fibrillation * Thoracic metal implants (cardiac stents allowed) * Pacemaker or internal defibrillator * Pregnancy (if after 20-week period)\* or lactation * Patient unable to lie down (i.e. supine position up to a maximum 25 degree tilt) or stay still on the examination bed * Patient unable to understand the informed consent process and/or has a poor understanding of English (e.g. English-speaking relative/translator not available) * There should not be any effect on pregnancy due to the non-invasive nature of the device. Pregnancy after the 20-week period excluded from the study due to the size and position of the foetus and unknown possibility of picking up the foetal heartbeat, rendering the scan non-usable for study requirements

Locations (1)

South Warwickshire NHS Trust

Warwick, Warwickshire, United Kingdom

Outcomes

Primary Outcomes

MCG parameter extraction

To extract parameters from MCG scans to identify key characteristics (markers) for myocardial infarction

Time frame: From baseline scan

Secondary Outcomes

MCG parameter analysis

To use the markers identified to differentiate between abnormal (post MI) images and normal (healthy volunteer) images using evaluation performance measures

Time frame: From baseline scan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.